Re- understanding of refractory hepatitis C: progress in antiviral therapy strategies for hepatitis C

Dou XiaoGuang; Ding Yang

doi:10.3969/j.issn.1001-5256.2014.06.002

Issue 6

Jun. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(6): 485-488

PDF( 351 KB)

Re- understanding of refractory hepatitis C: progress in antiviral therapy strategies for hepatitis C

DOI: 10.3969/j.issn.1001-5256.2014.06.002

Department of Infectious Diseases, Shengjing Hospital Affiliated to China Medical University

Received Date: 2014-04-06
Published Date: 2014-06-20

Abstract

Abstract

It has been nearly 20 years from the discovery of hepatitis C virus ( HCV) and clinical diagnosis of hepatitis C to antiviral therapy with interferon, and significant progress has been made. Substantial changes have taken place in both the concept and strategy for antiviral treatment of hepatitis C, with more and more direct- acting antiviral agents emerging in recent years; these changes are as follows: from the control of HCV to clinical cure, from a sustained virologic response ( SVR) rate around 30% with conventional interferon therapy to an SVR rate of 70%- 80% with standard therapy with pegylated interferon and ribavirin, and from evaluating the difficulty of treatment based on genotypes and viral load to determining the treatment strategy according to host IL28B genotypes and response patterns ( rapid virologic response and complete early virologic response) . The progress in antiviral therapy strategies for hepatitis C is systematically reviewed for re-understanding of refractory hepatitis C.
- hepatitis C,
- antiviral agents,
- review

FullText(HTML)

References(25)

References

[1]DOU XG.The relevant factors and strategies related efficacy with standard of care in chronic hepatitis C treatment naive patients[J].Chin J Hepatol, 2013, 21 (6) :406-407. (in Chinese) 窦晓光.影响丙型肝炎初治患者标准化治疗疗效的相关因素及对策[J].中华肝脏病杂志, 2013, 21 (6) :406-407.

[2]FRIED MW, SHIFFMAN ML, RDEEY KR, et al.Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection[J].N Engl J Med, 2002, 347 (13) :975-982.

[3]JENSEN DM, MORGAN TR, MARCELLIN P, et al.Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd) /ribavirin therapy[J].Hepatology, 2006, 43 (5) :954-960.

[4] European Association for the Study of the Liver.EASL Clinical Practice Guidelines:management of hepatitis C virus infection[J].J Hepatol, 2011, 55 (2) :245-264.

[5]GHANY MG, NELSON DR, STRADER DB, et al.An update on treatment of genotype 1 chronic hepatitis C virus infection:2011practice guideline by the American Association for the Study of Liver Diseases[J].Hepatology, 2011, 54 (4) :1433-1444.

[6]MYERS RP, RAMJI A, BILODEAU M, et al.An update on the management of hepatitis C:consensus guidelines from the Canadian Association for the Study of the Liver[J].Can J Gastroenterol, 2012, 26 (6) :359-375.

[7] BRUNO S, SHIFFMAN ML, ROBERTS SK, et al.Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis[J].Hepatology, 2010, 51 (2) :388-397.

[8]MOUSA O, PHAM LE, EGWIM CI, et al.Efficacy, tolerability and discontinuations of the current direct acting agents in chronic hepatitis C patients with cirrhosis[J].Hepatology, 2012, 56 (Suppl 4) :1049A.

[9]SAAB S, HUNT DR, STONE MA, et al.Timing of hepatitis C antiviral therapy in patients with advanced liver disease:a decision analysis model[J].Liver Transpl, 2010, 16 (6) :748-759.

[10]PRATI GM, RUMI M, AGHEMO A, et al.The influence of liver fibrosis on the outcome of pegylated interferon and ribavirin antiHCV therapy:a sub-analysis of the MIST study[J].Hepatology, 2009, 50 (Suppl 4) :687A.

[11]VEZALI E, AGHEMO A, COLOMBO M.A review of the treatment of chronic hepatitis C virus infection in cirrhosis[J].Clin Ther, 2010, 32 (13) :2117-2138.

[12]BRUNO S, SHIFFMAN ML, ROBERTS SK, et al.Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis[J].Hepatology, 2010, 51 (2) :388-397.

[13]ZEUZEM S, PAWLOTSKY JM, LUKASIEWICZ E, et al.International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C[J].J Hepatol, 2005, 43 (2) :250-257.

[14]DAVIS GL, WONG JB, MCHUTCHISON JG, et al.Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C[J].Hepatology, 2003, 38 (3) :645-652.

[15]FERENCI P, FRIED MW, SHIFFMAN ML, et al.Predicting sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD) /ribavirin[J].J Hepatol, 2005, 43 (3) :425-433.

[16]YU JW, WANG GQ, SUN LJ, et al.Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin[J].J Gastroenterol Hepatol, 2007, 22 (6) :832-836.

[17]ROMERO-GMEZ M, DEL MAR VILORIA M, ANDRADE RJ, et al.Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients[J].Gastroenterology, 2005, 128 (3) :636-641.

[18]CALVARUSO V, MAZZA M, ALMASIO PL.Pegylated-interferon-α (2a) in clinical practice:how to manage patients suffering from side effects[J].Expert Opin Drug Saf, 2011, 10 (3) :429-435.

[19]FREDLUND P, HILLSON JL, GRAY TE, et al.Peginterferon lambda-1a is associated with less autoimmune thyroid disease and serious autoimmune disease than peginterferonα-2a when used in combination with RBV for the treatment of chronic hepatitis C virus infection[J].Hepatology, 2012, 56 (Suppl 4) :571A.

[20]MUIR AJ, SRINIVASAN S, SAPRA S, et al.Peginterferon lambda-1a is less likely to induce clinically significant neuropsychiatric sympotoms during the treatment of chronic hepatitis C virus infection, compared to peginterferonα-2a[J].Hepatology, 2012, 56 (Suppl 4) :578A.

[21]POORDAD F, McCONE J JR, BACON BR, et al.Boceprevir for untreated chronic HCV genotype 1 infection[J].N Engl J Med, 2011, 364 (3) :1195-1206.

[22]BRUNO S, VIERLING JM, ESTEBAN R, et al.Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis[J].J Hepatology, 2013, 58 (3) :479-487.

[23]BACON BR, GORDON SC, LAWITZ E, et al.Boceprevir for previously treated chronic HCV genotype 1 infection[J].N Engl J Med, 2011, 364 (13) :1207-1217.

[24]SHERMAN KE, FLAMM SL, AFDHAL NH, et al.Response-guided telaprevir combination treatment for hepatitis C virus infection[J].N Engl J Med, 2011, 365 (11) :1014-1024.

[25]POODAD F, FRIED MW, ZEUZEM S, et al.Efficacy and tolerability of TMC435 150 mg once daily with peginterferonα-2a and ribavirin for treatment of HCV genotype 1 infection in patients with Metavir score F3 and F4 (PILLAR and ASPIRE trials) [J].Hepatology, 2012, 56 (Suppl 4) :233A.

Relative Articles

[1]	Ru JIA, Pingping ZHANG, Yuan YUAN, Yiyang HU, Qin FENG. Differences and application value of plasma bile acids in tumors of the liver[J]. Journal of Clinical Hepatology, 2024, 40(10): 2042-2048. doi: 10.12449/JCH241018
[2]	ZHANG ZhongLin, YUAN YuFeng. Key operating points of laparoscopic hepatectomy for liver tumor in difficult locations[J]. Journal of Clinical Hepatology, 2020, 36(12): 2663-2666. doi: 10.3969/j.issn.1001-5256.2020.12.006
[3]	Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
[4]	Wang ZhiYu, Gu SanWei, Chen XiaoQian, Cai YanJun. Clonorchiasis misdiagnosed as hepatic tumor: a case report[J]. Journal of Clinical Hepatology, 2018, 34(3): 602-603. doi: 10.3969/j.issn.1001-5256.2018.03.033
[5]	Qi Fei, Tang YingMei. The mechanism of chenodeoxycholic acid and its derivatives in hepatobiliary tumor[J]. Journal of Clinical Hepatology, 2018, 34(5): 1115-1118. doi: 10.3969/j.issn.1001-5256.2018.05.041
[6]	Chen HaiOu, Liu Shi, Lin YiHe. Expression of M30 and CCL20 in serum in patients with HBV-related acute-on-chronic liver failure and their clinical significance[J]. Journal of Clinical Hepatology, 2018, 34(4): 806-809. doi: 10.3969/j.issn.1001-5256.2018.04.022
[7]	Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
[8]	Zhao Zhao, Qi WenQian, Zhao Ping. Research advances in insulin-like growth factor 1 receptor and its pathway in diagnosis and treatment of primary liver cancer[J]. Journal of Clinical Hepatology, 2017, 33(4): 763-768. doi: 10.3969/j.issn.1001-5256.2017.04.038
[9]	Kong Li, Jin Meng, Zhao SuXian. Role of tumor necrosis factor- alpha- induced protein 8-like 2 in development and progression of liver and gastrointestinal tumors[J]. Journal of Clinical Hepatology, 2017, 33(1): 175-179. doi: 10.3969/j.issn.1001-5256.2017.01.041
[10]	Chen Wei, Zhou Yun, Gong JianPing. Role of tumor-associated macrophages in development and progression of primary liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(7): 1422-1424. doi: 10.3969/j.issn.1001-5256.2016.07.048
[11]	Wang JinWei, Zhang YaMin. Research advances in methods for determination of tumor boundary in hepatectomy[J]. Journal of Clinical Hepatology, 2016, 32(2): 374-377. doi: 10.3969/j.issn.1001-5256.2016.02.039
[12]	Lin Kun, Ci DanWangJiu, Chang ZhiHui, Liu ZhaoYu. Clinical value of circulating micro RNAs in hepatic,biliary and pancreatic carcinomas[J]. Journal of Clinical Hepatology, 2015, 31(5): 790-795. doi: 10.3969/j.issn.1001-5256.2015.05.040
[13]	Chen XuXiao, Chen YongJun. PI3K / Akt / mTOR signaling pathway and malignant hepatobiliary tumors[J]. Journal of Clinical Hepatology, 2015, 31(6): 989-991. doi: 10.3969/j.issn.1001-5256.2015.06.040
[14]	Wang WuChen, Zhou YongNing. Research progress in tumor- associated antigen antibodies for diagnosis of liver cancer[J]. Journal of Clinical Hepatology, 2014, 30(6): 573-576. doi: 10.3969/j.issn.1001-5256.2014.06.025
[15]	Fang ZiYan, Huang Long, Li Gong. Research progress in radiotherapy for liver tumors reported in 2013 ASTRO Annual Meeting[J]. Journal of Clinical Hepatology, 2014, 30(4): 383-385. doi: 10.3969/j.issn.1001-5256.2014.04.025
[16]	Ji Bo, Liu YaHui. Research advances in role of myeloid- derived suppressor cells in tumorigenesis[J]. Journal of Clinical Hepatology, 2014, 30(9): 939-943. doi: 10.3969/j.issn.1001-5256.2014.09.026
[17]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[19]	Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365.

Supplements(0)

Cited By

Cited by

Periodical cited type(30)

1.	汪淑佳，俞黎. 多学科团队诊疗模式下的PDCA循环管理在梗阻性黄疸患者围术期护理中的应用效果分析. 中国社区医师. 2025(02): 96-98 .
2.	易衡，何芬，王曦，冯谦，唐杰，卿小琼，孙菲菲，陈重. 超声引导下PTCD治疗晚期MOJ疗效及预后因素分析. 武汉大学学报(医学版). 2024(07): 814-819 .
3.	李鸿. 老年晚期恶性梗阻性黄疸患者实时超声弹性成像定量分析对PTCD预后的预测价值. 昆明医科大学学报. 2023(01): 122-127 .
4.	李鸿. 老年晚期恶性梗阻性黄疸患者实时超声弹性成像定量分析对PTCD预后的评估价值. 昆明医科大学学报. 2023(02): 150-155 .
5.	梁亚丽，李馨，夏俊杰. 胰腺癌梗阻性黄疸患者经皮穿刺胆管引流术后发生胰腺炎的危险因素分析. 实用癌症杂志. 2023(08): 1321-1324 .
6.	杨立新，刘茜，周晶晶，唐亚丹，傅鹏，戴峰，白淑芬. 不同方法PTCD应用于梗阻性黄疸治疗中的体会. 现代医用影像学. 2023(12): 2229-2231+2235 .
7.	华建军. 超声引导下经皮肝穿刺胆管引流术治疗对阻塞性黄疸病人胆红素水平与肝功能的影响研究. 贵州医药. 2022(02): 226-227 .
8.	黄道琼，沈小叶，刘骏，刘月娥，陈瑜. 回授法在经皮肝穿刺胆管引流术后的应用. 介入放射学杂志. 2022(03): 294-297 .
9.	彭赵宏，张德志，施万印，赵本胜，熊壮，汪名权，宋文，陶龙香，刘斌，张帅，程翔. ~(125)I粒子支架治疗恶性梗阻性黄疸支架通畅时间的影响因素分析. 安徽医科大学学报. 2022(04): 645-649 .
10.	王玮，陈熙，罗丹，李启祥，尹合坤. 不同姑息性引流术对低位恶性梗阻性黄疸的近远期疗效及安全性分析. 当代医学. 2022(19): 39-42 .
11.	买买提·瓦司力，高旭升，司俊杰，徐峰. 经皮肝穿引流和支架植入在恶性梗阻性黄疸患者治疗的疗效评价. 新疆医学. 2022(07): 770-772+809 .
12.	王颖. 彩超引导经皮穿刺肝胆管引流术治疗梗阻性黄疸的临床研究. 中国医疗器械信息. 2022(15): 123-125 .
13.	宋飞，向盈盈，车佳音，李红阳，徐文勇，魏凌潇，黄明. 胆道~(125)I粒子支架与金属裸支架治疗Bismuth Corlette Ⅲ型胆管癌合并梗阻性黄疸的临床对比. 昆明医科大学学报. 2022(11): 85-89 .
14.	冉庆. ERCP联合PTCD胆总管支架置入胆管引流治疗恶性梗阻性黄疸的临床价值. 医学食疗与健康. 2021(04): 86-87 .
15.	王锦程，余佩和，苏松，李波. 经内镜鼻胆管引流术与经内镜胆道支架置入术在低位恶性梗阻性黄疸术前胆道引流效果比较的Meta分析. 临床肝胆病杂志. 2021(04): 863-867 . 本站查看
16.	马博，周军，周京涛，李建刚，王俊. 胆道支架植入治疗恶性梗阻性黄疸术后并发症的发生因素分析. 现代生物医学进展. 2021(07): 1283-1286 .
17.	张建松，侯森，崔虎啸. 超声引导下经皮肝穿刺胆道引流联合胆管复合支架置入术治疗晚期肝外胆管癌的效果. 癌症进展. 2021(09): 931-934 .
18.	张华安，周晓芳，蒋易君，张淏嘉. NRS-2002联合炎症反应标志物预测恶性梗阻性黄疸患者预后的Nomogram模型构建. 山东医药. 2021(16): 35-40 .
19.	石书伟，王劲. 经皮肝穿刺胆道引流联合金属支架植入术对恶性梗阻性黄疸的影响. 黑龙江医学. 2021(15): 1608-1609 .
20.	宋英茜，陶冶. 梗阻性黄疸经皮肝穿刺胆道引流术后胆道感染的病原菌特点及其危险因素分析. 中国实用乡村医生杂志. 2021(02): 33-36 .
21.	张志强，韩涛，崔钢，王奕，蔡恒烈，廖骞. 右肝管入路单通道横跨左右肝管引流治疗汇管区恶性梗阻性黄疸的临床研究. 中国普通外科杂志. 2021(12): 1503-1508 .
22.	傅建英. 内镜介入治疗急性梗阻性黄疸的疗效及对患者炎症因子的影响. 中外医疗. 2021(33): 57-60 .
23.	李蔚，王锡斌，崔卫东，杨青，刘会苗，杨金雨，王锡斌. 超声引导下经皮经肝胆管穿刺引流术治疗急性梗阻性化脓性胆管炎患者疗效分析. 实用肝脏病杂志. 2020(03): 447-450 .
24.	李磊. 胆道支架联合经皮肝穿刺胆管引流术对晚期恶性梗阻性黄疸的临床应用价值. 名医. 2020(08): 85-86 .
25.	张蓓，答秀维，张乐. 经皮肝穿刺胆道外引流治疗恶性梗阻性黄疸疗效及对患者细胞免疫功能、血清直接胆红素、超敏C反应蛋白水平的影响. 陕西医学杂志. 2020(10): 1249-1252 .
26.	朱超，刘会春，胡小四，庞青，陈邦邦，李传涛. 胆道双支架联合~(125)I粒子腔内照射治疗恶性肝门部胆道梗阻的疗效分析. 介入放射学杂志. 2020(11): 1100-1104 .
27.	姜磊，都晓英，孙医学，张大坤，周凯，徐建中，陈芳芳. PTBS术治疗恶性梗阻性黄疸的临床价值及预后因素分析. 蚌埠医学院学报. 2019(09): 1202-1205+1209 .
28.	江新华. 64层螺旋CT3D成像与MRCP成像技术对胆道梗阻性疾病的诊断价值. 江西医药. 2019(11): 1336-1340 .
29.	吴子鑫，吴申伟. 经皮肝穿刺胆道支架植入治疗对恶性梗阻性黄疸患者肝功能指标、炎症指标的影响. 齐齐哈尔医学院学报. 2019(24): 3098-3099 .
30.	武飞. 经皮肝穿刺胆管引流术与Roux-en-Y胆肠吻合术治疗恶性梗阻性黄疸患者的对比研究. 中国药物与临床. 2019(23): 4098-4100 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (327) PDF downloads(125)

Re- understanding of refractory hepatitis C: progress in antiviral therapy strategies for hepatitis C

DOI: 10.3969/j.issn.1001-5256.2014.06.002